Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1

A method of alleviating, and/or treating a pathology selected from the group consisting of HMGB-1 associated pathologies, RAGE-related pathologies, auto immune disease, systemic inflammatory response syndrome, cardiovascular affection, dermatological disease, and neurological disease comprising administering to a patient an effective amount of a polymer conjugate of the human and/or non human wild type HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A), a polypeptide variant of the human and/or non human HMGB-1 Box-A, or of a biologically active fragment of HMGB-1 Box-A, whereby the amino acid sequence of said polypeptide variant differs from the amino acid sequence of the wild type HMGB-1 Box-A by the mutation of one or more single amino acid.